Get the Stockscreener App
27.65
1.81%
-0.51
Spyglass Pharma Inc stock is traded at $27.65, with a volume of 81,362.
It is down -1.81% in the last 24 hours and up +5.29% over the past month.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
See More
Previous Close:
$28.16
Open:
$28.22
24h Volume:
81,362
Relative Volume:
0.62
Market Cap:
$924.84M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-5.2274
EPS:
-5.2894
Net Cash Flow:
-
1W Performance:
-5.73%
1M Performance:
+5.29%
6M Performance:
+16.47%
1Y Performance:
+0.00%
1-Day Range:
$26.64
$28.22
1-Week Range:
$26.64
$29.96
52-Week Range:
$17.06
$30.56
Spyglass Pharma Inc Stock (SGP) Company Profile
Name
Spyglass Pharma Inc
Sector
Industry
Phone
949-284-6904
Address
27081 ALISO CREEK ROAD, ALISO VIEJO
Compare SGP vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGP
Spyglass Pharma Inc
|
27.65 | 924.84M | 0 | 0 | 0 | -5.2894 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyglass Pharma Inc Stock (SGP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | H.C. Wainwright | Buy |
| Mar-03-26 | Initiated | Citigroup | Buy |
| Mar-03-26 | Initiated | Jefferies | Buy |
| Mar-03-26 | Initiated | Leerink Partners | Outperform |
| Mar-03-26 | Initiated | Stifel | Buy |
Spyglass Pharma Inc Stock (SGP) Latest News
Top Spyglass Pharma (SGP) Competitors 2026 - MarketBeat
Spyglass Pharma (NASDAQ:SGP) Upgraded at Wall Street Zen - MarketBeat
Spyglass Pharma (NASDAQ:SGP) Trading Down 5.3%Should You Sell? - MarketBeat
SpyGlass Pharma at H.C. Wainwright conference: glaucoma push gains ground - Investing.com Canada
SpyGlass Pharma at Citigroup summit: glaucoma lens nears phase iii By Investing.com - Investing.com Canada
SpyGlass Pharma (SGP) Holds Near $27.55 as Traders Eye the $28.93 CeilingBreadth Thrust - dars.gov.et
Partner Spotlight - City of Irvine (.gov)
SpyGlass Pharma Expands to Bigger HQ in Irvine - Orange County Business Journal
SpyGlass Pharma, Inc. (NASDAQ: SGP) Share Price, SGP Stock News, SGP Share Price & Updates - Kalkine
SpyGlass Pharma to Participate in Upcoming Investor Conferences - GlobeNewswire
SpyGlass Pharma (SGP) Slides 1.89% to $26.42 as Support Level at $25.1 Comes into ViewChart Pattern Alerts - dars.gov.et
SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space - Moomoo
SpyGlass (SGP) Trading: Closes 1.00% Lower at $26.25; Traders Can Monitor the $24.94-$27.56 Range for the Current SessionContinuation Pattern Picks - vinanet.vn
SpyGlass (SGP) Earnings Reading: EPS Misses Its Estimate in the Available Record; Share Move - vinanet.vn
SpyGlass (SGP) Update: Gains 2.13% to Reach $26.79 for the Current Session; Price Context - dars.gov.et
SpyGlass (SGP): Finishes 1.91% Lower at $26.71; Technical Setup: the Current Price Sits Inside the Supplied Technical Range in the Available RecordWyckoff Accumulation - vinanet.vn
SpyGlass (SGP) Financial Update: Profit Per Share Falls Below Its Benchmark under the Current Snapshot - vinanet.vn
SpyGlass Pharma (SGP) Slides 2.4% as Shares Test Mid-Range Support ZoneBlock Trade Flow - vinanet.vn
Spyglass Pharma (SGP) Insider Trading Activity 2026 $SGP - MarketBeat
Spyglass Pharma (NASDAQ:SGP) Upgraded to "Moderate Buy" at Raymond James Financial - MarketBeat
Analysts Offer Insights on NA Companies: Ottobock SE & Co. KGaA (OtherOBCKF), SpyGlass Pharma (Nasdaq: SGP) and Figure Technology Solutions, Inc. Class A (FIGR) - The Globe and Mail
Raymond James Initiates SpyGlass Pharma(SGP.US) With Buy Rating, Announces Target Price $39 - Moomoo
Raymond James initiates SpyGlass Pharma stock coverage with outperform rating - Investing.com
Raymond James Initiates SpyGlass Pharma at Outperform, With $39 Price Target - finance.yahoo.com
Q3 EPS Estimates for Spyglass Pharma Decreased by Analyst - MarketBeat
SpyGlass Pharma Reports Q2 Financials, Provides Corporate Updates - visionmonday.com
SpyGlass Pharma Ord shs (Proposed) (SGP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Spyglass Pharma, Inc. (NASDAQ:SGP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times
SpyGlass Pharma 2Q 2026: Net loss $(19.9)M, EPS $(0.59) — 10-Q Summary - TradingView
[10-Q] SpyGlass Pharma, Inc. Quarterly Earnings Report - Stock Titan
SpyGlass Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
SpyGlass Pharma reports $19.9M Q2 net loss, $234.2M cash and investments as of June 30, 2026 - TradingView
SpyGlass Pharma Q2 net loss widens on higher expenses - TradingView
SpyGlass Pharma Insiders Enjoying US$1.1m Appreciation On US$2.16m Investment - webull.com
SpyGlass Pharma (SGP) Rallies 3.08% to $24.41 as Ophthalmic Focus Draws Fresh BuyingLow Vol Factor - dars.gov.et
SpyGlass Pharma (SGP) Climbs 5.5% as Bulls Eye Resistance at $26.24Catalyst Driven Stocks - dars.gov.et
22,536,164 Common Stock of SpyGlass Pharma, Inc. are subject to a Lock-Up Agreement Ending on 5-AUG-2026. - marketscreener.com
SpyGlass Pharma (SGP) Climbs 1.34%, Nears Key Resistance at $23.01Time Weighted Price - careplusvn.com
SGP|SpyGlass Pharma Ord shs (Proposed)|Price:20.490|Chg%:-0.390 - TradingKey
Spyglass Pharma (NASDAQ:SGP) Shares Gap UpStill a Buy? - MarketBeat
SpyGlass Pharma, Inc. Revenue Breakdown – NASDAQ:SGP - TradingView
SpyGlass Pharma Q1 2026 Earnings: EPS Misses Estimates as Company Advances PipelineWeak Earnings Momentum - vinanet.vn
SpyGlass Pharma (SGP) Jefferies Global Healthcare Conference 2026 Summary - Quartr
SpyGlass Pharma Holds Steady Near Support as Traders Eye Key LevelsIceberg Order - dars.gov.et
SpyGlass Pharma (SGP) Drops 4.77% as Key Support Levels Are TestedFade Trade - dars.gov.et
Glaukos Glaucoma Tech Trade Secrets Suit Survives Dismissal Bids - Bloomberg Law News
SpyGlass Pharma (SGP) Rallies 2.67%, Tests Key Resistance LevelRatio Spread Trade - dars.gov.et
SGP Q1 2026 Earnings: EPS Misses Estimates as Revenue Remains AbsentEarnings Miss Alert - dars.gov.et
SpyGlass Pharma Inc. (SGP) Q1 2026 Earnings: Wider-Than-Expected Loss Triggers Double-Digit Selloff - dars.gov.et
Spyglass Pharma Inc Stock (SGP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):